<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13381">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932722</url>
  </required_header>
  <id_info>
    <org_study_id>RIPC_propofol</org_study_id>
    <secondary_id>1605-079-761</secondary_id>
    <nct_id>NCT02932722</nct_id>
  </id_info>
  <brief_title>Effect of Propofol on Cardioprotective Role of Remote Ischemic Preconditioning (RIPC)</brief_title>
  <official_title>Effect of Propofol on Cardioprotective Role of Remote Ischemic Preconditioning (RIPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves research using human subjects (cardiac surgical patients) to evaluate
      the effect of remote ischemic preconditioning (RIPC) on cardioprotective outcomes. RIPC
      applied to upper or lower extremities has been shown cardioprotective role by lowering
      release of cardiac troponin in patients with cardiac diseases. However, it is not clear
      whether anesthetics, such as propofol or sevoflurane, may impair the cardioprotective effect
      of RIPC in cardiac surgical patients. Therefore, the purpose of the study is to compare the
      effects of anesthetics on cardioprotection of RIPC in patients undergoing cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing cardiac surgery using cardiopulmonary bypass will be randomized to
      control, propofol, or sevoflurane group. Patients in the control group will receive remote
      ischemic preconditioning (RIPC) on their upper arms before anesthetic induction. Patients in
      the propofol or sevoflurane groups will receive RIPC after anesthetic induction using
      propofol or sevoflurane, respectively. In all patients, arterial blood samples will be
      obtained before and after each RIPC. From the samples, human dialysate will be obtained and
      perfused to rat heart through Langendorff apparatus before ischemia-reperfusion injury to
      the rat heart. Infarct size of the sectioned rat heart will be compared among the three -
      control, propofol, and sevoflurane - groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size of the rat heart</measure>
    <time_frame>2 day after ischemia-reperfusion injury</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac troponin I after surgery</measure>
    <time_frame>72 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular and cerebrovascular events</measure>
    <time_frame>Through study completion, average of 2 weeks before hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients in the control group will be receive remote ischemic preconditioning before anesthetic induction (before exposure to any anesthetic).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the propofol groups will be receive remote ischemic preconditioning after anesthetic induction using propofol, as a main anesthetic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the sevoflurane groups will be receive remote ischemic preconditioning after anesthetic induction using sevoflurane, as a main anesthetic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Not receiving any anesthetic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Receiving propofol anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <other_name>Receiving sevoflurane anesthesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA class I~III patients undergoing cardiac surgery using cardiopulmonary bypass

        Exclusion Criteria:

          -  Cardiac surgery without using cardiopulmonary bypass

          -  Descending thoracic aortic surgery

          -  Strenuous exercise, excessive alcohol or caffeine intake 24 hours before remote
             ischemic preconditioning

          -  Left ventricular ejection fraction &lt; 30%

          -  Uncontrolled hypertension or diabetes mellitus

          -  Severe renal or hepatic dysfunction

          -  Patients on hemodialysis

          -  Patients with arterio-venous fistula on arms or any reason to protect arms

          -  Peripheral vascular or nerve disease, bleeding tendency

          -  Preoperative use of IABP, ECMO, or ventricular assist devices

          -  Emergency operation, redo operation

          -  Refuse to enroll

          -  Pregnancy

          -  Preoperative use of beta-blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunseok Jeon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunseok Jeon, MD, PhD</last_name>
    <phone>82-2-2072-2465</phone>
    <email>jeonyunseok@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Youn Joung Cho, MD</last_name>
    <phone>82-2-2072-3108</phone>
    <email>mingming7@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunseok Jeon, MD, PhD</last_name>
      <phone>82-2-2072-2467</phone>
      <email>jeonyunseok@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yunseok Jeon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 6, 2016</lastchanged_date>
  <firstreceived_date>September 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yunseok Jeon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Propofol</keyword>
  <keyword>Sevoflurane</keyword>
  <keyword>Preconditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
